C4 Therapeutics, Inc.

NASDAQ:CCCC

Biotechnology

Healthcare
$2.48 +2.06%

+$0.08 today

Market cap
$325.01M
Beta
2.93
P/E (TTM)
-4.9
EPS (TTM)
-$0.82
52W Low $1.36High $4.60

Volume 2.75M

Average 2.76M

CCCC Income Before Tax

Profit after all operating and non-operating items but before income tax.

C4 Therapeutics, Inc.NASDAQ: CCCC

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax remains negative

Q1 FY2026 income before tax was -$25.13M, compared with -$26.32M a year earlier. Trailing-twelve-month income before tax was -$103.68M.

Context

  • Income before tax amounted to 291.7% of revenue in FY2025, down 3.9 pp from a year earlier.
  • Income before tax grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income before tax holds near -$25.13M or moves back toward the trailing-twelve-month quarterly average of -$25.92M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$25.13M-23.4% QoQ
Last fiscal yearDec 2025
-$104.87M+0.3% YoY
LTMMar 2026
-$103.68M-0.5% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+4.5%——
1 year+0.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(104.87M) USD
Year-over-year change
+0.3%

Income Before Tax vs competitors

How CCCC compares with its peers on the latest reported figures

  • Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -0.5% is the 5th highest of 9, against a peer median of +0.2%.
  • Income before tax amounts to 297.4% of revenue for CCCC, versus a peer median of 1406.8%.
CCCC Competitors
Income Before Tax for CCCC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CDXSCodexis, Inc.LTM Mar 2026-$31.92M USD+57.1%—40.9%
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026-$47.84M USD+17.8%—2454.6%
OABIOmniAb, Inc.LTM Mar 2026-$53.37M USD+21.7%—184.6%
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026-$68.55M USD-32.0%—3842.2%
MOLNMolecular Partners AGLTM Mar 2026-CHF 72.05M CHF-17.4%——
PEPGPepGen Inc.LTM Mar 2026-$77.15M USD+24.9%——
CCCCC4 Therapeutics, Inc.LTM Mar 2026-$103.68M USD-0.5%—297.4%
SGMOSangamo Therapeutics, Inc.LTM Mar 2026-$124.02M USD-55.8%—358.9%
ARMPArmata Pharmaceuticals, Inc.LTM Mar 2026-$282.61M USD-66241.3%—9554.2%
Peer median (excluding CCCC) —+0.2%—1406.8%

Competitors are the stored peer set for CCCC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue45.79M31.1M20.76M35.58M35.95M
Cost of Revenue007.74M07.98M
Gross Profit45.79M31.1M13.02M35.58M27.97M
Gross Margin100.0%100.0%62.7%100.0%77.8%
Research & Development94.67M117.84M117.71M110.64M104.24M
Selling, General & Admin33.25M42.79M42.08M42.12M36.2M
Operating Expenses127.92M160.63M152.05M155.2M132.46M
Depreciation & Amortization1.49M1.68M7.74M1.82M1.96M
EBITDA(80.26M)(124.28M)(122.1M)(103.37M)(102.91M)
EBITDA Margin-175.3%-399.7%-588.3%-290.5%-286.3%
Operating Income(82.13M)(129.53M)(139.03M)(119.61M)(104.49M)
Operating Margin-179.4%-416.6%-669.8%-336.1%-290.7%
Interest Income387K3.58M9.81M14.43M10.35M
Interest Expense2.15M2.22M1.37M00
Other Income / Expenses(1.76M)1.36M7.82M14.43M(384K)
Income Before Tax(83.89M)(128.18M)(131.21M)(105.19M)(104.87M)
Pre-Tax Margin-183.2%-412.2%-632.2%-295.6%-291.7%
Income Tax Expense001.28M131K121K
Net Income(83.89M)(128.18M)(132.49M)(105.32M)(104.99M)
Net Margin-183.2%-412.2%-638.3%-296.0%-292.1%
EPS (Basic)(1.82)(2.62)(2.67)(1.52)(1.27)
EPS (Diluted)(1.82)(2.62)(2.67)(1.52)(1.27)
Weighted Avg Shares46.04M48.86M49.64M69.37M82.89M
Weighted Avg Shares (Diluted)46.04M48.86M49.64M69.37M82.89M

C4 Therapeutics, Inc.

NASDAQ:CCCC

Intrinsic Alpha fair value

Locked

Current Price

$2.48

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.